05:54 AM EDT, 10/23/2026 (MT Newswires) -- Berenberg reiterated its buy rating on Fresenius SE (FRE.F) as analysts took note of the German healthcare company's "increasingly profitable" growth vectors. "The market values Fresenius as a hospital-heavy conglomerate and has not rewarded its shift towards its faster-growing, increasingly profitable growth vectors - biosimilars (Biopharma), Nutrition and MedTech - which are funded by its cash-generative hospital (Helios) and IV generics businesses (Pharma). EBIT of the company's growth vectors overtook Pharma in Q4 2025 and was 16% larger in H1 2026," according to a Friday note. As such, the research firm expects the company's EPS to grow at a high single-digit rate annually over the midterm, with its 2027 estimate 2% above consensus. "Management guides conservatively and has raised guidance on four occasions in two years; therefore, we think risk to consensus is skewed to the upside," Berenberg added. Against this backdrop, Berenberg raised the stock's price target to 54 euros from 50 euros. Meanwhile, near-term catalysts include the group's third-quarter results on Nov. 4, which would include the first Helios Germany month without the surcharge, among others.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.